Figure 1: Gastrointestinal Disorders, US, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987–2014
Figure 2: Gastrointestinal Disorders, US, Post-Marketing-Approval Sales Performance of First-in-Class Products Across the Pharmaceutical Industry ($m), 2006–2013
Figure 3: Gastrointestinal Disorders, Global, Market by Molecule Type, 2019
Figure 4: Gastrointestinal Disorders, Global, Market by Molecular Target Class, 2019
Figure 5: Gastrointestinal Disorders, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2019
Figure 6: Gastrointestinal Disorders, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 7: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Stage of Development, 2019
Figure 8: Gastrointestinal Tract Disorders, Global, Pipeline for Key Indications by Molecule Type, 2019
Figure 9: Gastrointestinal Disorders, Global, Pipeline by Molecular Target Class and Stage of Development, 2019
Figure 10: Gastrointestinal Disorders, Global, Breakdown of Cytokine Signaling, GPCR and Transcription Factor and Regulation Molecular Target Classes, 2019
Figure 11: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Molecular Target Class, 2019
Figure 12: Gastrointestinal Disorders, Global, Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 13: Gastrointestinal Disorders, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2019
Figure 14: Gastrointestinal Disorders, Global, Pipeline for Key Indications by Molecular Target Class and First-in-Class Status, 2019
Figure 15: Gastrointestinal Disorders, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class (%), 2019
Figure 16: Gastrointestinal Disorders, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Figure 17: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 1)
Figure 18: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 2)
Figure 19: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 3)
Figure 20: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 4)
Figure 21: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 5)
Figure 22: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 6)
Figure 23: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 7)
Figure 24: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 8)
Figure 25: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 9)
Figure 26: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 10)
Figure 27: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 11)
Figure 28: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 12)
Figure 29: Gastrointestinal Disorders, Global, List of All Pipeline Products, 2019 (part 13)
Figure 30: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Crohn’s Disease, 2019 (part 1)
Figure 31: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Crohn’s Disease, 2019 (part 2)
Figure 32: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Ulcerative Colitis, 2019 (part 1)
Figure 33: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Ulcerative Colitis, 2019 (part 2)
Figure 34: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 1)
Figure 35: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 2)
Figure 36: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 3)
Figure 37: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Nonalcoholic Steatohepatitis, 2019 (part 4)
Figure 38: Gastrointestinal Disorders, Global, First-in-Class Matrix Assessment for Celiac Disease, 2019
Figure 39: Gastrointestinal Disorders, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2014
Figure 40: Gastrointestinal Disorders, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006–2014
Figure 41: Gastrointestinal Disorders, Global, Licensing Deals by Region, Value and Year, 2006–2019
Figure 42: Gastrointestinal Disorders, Global, Licensing Deals by Key Indication, 2006–2019
Figure 43: Gastrointestinal Disorders, Global, Licensing Deals by Stage of Development, Deal Value, and Upfront Payment Value ($m), 2006–2019
Figure 44: Gastrointestinal Disorders, Global, Licensing Deals by Molecule Type and Molecular Target Class, 2006–2019
Figure 45: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006–2019 (part 1)
Figure 46: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006–2019 (part 2)
Figure 47: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006–2019 (part 3)
Figure 48: Gastrointestinal Disorders, Global, Licensing Deals with Disclosed Deal Values, 2006–2019 (part 4)
Figure 49: Gastrointestinal Disorders, Global, Co-development Deals by Region, Value and Year, 2006–2019
Figure 50: Gastrointestinal Disorders, Global, Co-development Deals by Key Indication, 2006–2019
Figure 51: Gastrointestinal Disorders, Global, Co-development Deals by Stage of Development and Deal Value, 2006–2019
Figure 52: Gastrointestinal Disorders, Global, Co-development Deals by Molecule Type and Molecular Target Class, 2006-2019
Figure 53: Gastrointestinal Disorders, Global, Co-development Deals with Disclosed Deal Values, 2006–2019 (part 1)
Figure 54: Gastrointestinal Disorders, Global, Co-development Deals with Disclosed Deal Values, 2006–2019 (part 2)
Figure 55: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 1)
Figure 56: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 2)
Figure 57: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 3)
Figure 58: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 4)
Figure 59: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 5)
Figure 60: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 6)
Figure 61: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 7)
Figure 62: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 8)
Figure 63: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 9)
Figure 64: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 10)
Figure 65: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 11)
Figure 66: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 12)
Figure 67: Gastrointestinal Disorders, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2019 (part 13)